Details for Patent: 11,382,926
Which drugs does patent 11,382,926 protect, and when does it expire?
Patent 11,382,926 protects VEKLURY and is included in one NDA.
Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-eight patent family members in twenty-three countries.
Summary for Patent: 11,382,926
| Title: | Methods for treating Arenaviridae and Coronaviridae virus infections |
| Abstract: | Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. |
| Inventor(s): | Michael O'Neil Hanrahan Clarke, Joy Yang Feng, Robert Jordan, Richard L. Mackman, Adrian S. Ray, Dustin Siegel |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US17/222,066 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,382,926 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,382,926
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,382,926
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016323604 | ⤷ Start Trial | |||
| Australia | 2020233714 | ⤷ Start Trial | |||
| Australia | 2023200990 | ⤷ Start Trial | |||
| Australia | 2025204785 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
